Mayne Pharma Launches Methylphenidate Extended-Release Capsules in the United States

Mayne Pharma Inc. recently announced the launch of methylphenidate extended-release capsules, 60 mg, in the United States. Methylphenidate is a generic alternative to Ritalin LA capsules, indicated for attention deficit hyperactivity disorder (ADHD). This launch complements the existing methylphenidate franchise that includes 20-mg, 30-mg, and 40-mg dose strengths.

“This will be the first generic alternative of the 60-mg dose strength, providing more choices to patients in terms of medication affordability. The launch of methylphenidate is Mayne Pharma’s sixth new product launch since the beginning of FY16,” Mayne Pharma’s CEO Scott Richards.

Mayne Pharma directly markets more than 50 products and has a growing pipeline of more than 40 generic and branded drug products targeting US markets with IMS sales greater than $6 billion.

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia, and Greenville, NC, with expertise in the formulation of complex oral dose forms, including highly potent compounds, controlled substances, modified-release products, and inherently unstable compounds. For more information, visit